US FDA guidance on biosimilars may be imminent
27/9/2011
The U.S. Food and Drug Administration (FDA) appears to be on the verge of issuing long-awaiting guidelines for the development of generic versions of complex biotechnology medicines. More...
Author: Greer Deal, Director of Global Regulatory Services (GRS)